Compare Eli Lilly And Co (LLY) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sirius XM Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,160.52 (market cap $1.02T), while Sirius XM Holdings Inc trades at $30.13 (market cap $10.30B). The key difference: Eli Lilly And Co is far larger — about 99× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.53%). Which is the better fit depends on your goals.
| LLY | SIRI | |
|---|---|---|
Market Cap | $1.02T | $10.30B |
Sector | Health | Media |
52-Week High | $1.24K | $31.22 |
52-Week Low | $625.65 | $19.92 |
Enterprise Value | $1.06T | $19.97B |
Dividend Yield | 0.6% | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Sirius XM (SIRI) trades at $30.68, up 0.29% with a bullish technical signal and strong analyst support (58% buy ratings). The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a 2024 loss. Recent developments include a strategic advertising partnership with YouTube and potential inclusion in the S&P MidCap 400 index.
The stock presents value characteristics with a P/E of 12.96 and P/B of 0.88, trading near the consensus price target of $31.17. Key risks include competitive pressures in media streaming and high debt levels despite recent improvement. Revenue stabilization and new partnerships provide catalysts, though execution risks remain in a challenging advertising environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
